SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cesarone, M. R.
Right arrow Articles by Cacchio, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cesarone, M. R.
Right arrow Articles by Cacchio, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study

M. R. Cesarone, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

G. Belcaro, PhD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy, Cardres{at}pe.abol.it

L. Pellegrini, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

A. Ledda, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

A. Di Renzo, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

G. Vinciguerra, PhD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

A. Ricci, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

G. Gizzi, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

E. Ippolito, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

F. Fano, MB

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

M. Dugall, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

G. Acerbi, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

M. Cacchio, MD

Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy

The aim of this independent study was to investigate differences in efficacy between HR, (0-[beta-hydroxyethyl]-rutosides) and D+H (500 mg, diosmin+hesperidin) in patients with chronic venous insufficiency (CVI). A first group of 90 patients with severe venous hypertension (CVI, ankle swelling) were randomized into an HR or a D+H group. The HR group received oral HR (2 g/day, 8 weeks); the D+H group received a 500 mg tablet 3 times daily for 8 weeks. A second group of comparable patients was included in a registry following the same study format. Patients were openly included; the 2 treatments were administered with the same methods and procedures. Clinical conditions were comparable to those described in the randomized study. Patients treated for at least 8 weeks were included in the registry. A number of physicians (specialists or general practitioners) included patients when they considered that clinical conditions were compatible with using 1 of the 2 treatments on the basis of their personal evaluation and experience. When cases were compatible with the registry, the prescribing physician communicated the case. Patients were evaluated without interfering with the treatment. Main targets of evaluation were skin flux at rest (RF), strain-gauge-derived rate of ankle swelling (RAS), and analogue symptoms score (ASLS). Ninety subjects completed the study in the first group; 122 in the second, registry group (total of 212 patients). The first and second (registry) groups and the 2 treatment groups were comparable for age and sex distribution. The pooled mean age was 42 years (SD ±5.5) in the HR group (46+62 patients) and 41.5 (SD ±6) in the D+H group (44+60 patients). Considering pooled data there were no differences in microcirculatory parameters between the pooled treatment groups at inclusion. A significant decrease (p<0.05) in RF and RAS was observed in the HR group at 8 weeks. The decrease in resting skin flux and in capillary filtration was associated with a significant improvement in signs/symptoms (analogue scale line) from an average of 9.4 (range 3-10) to 3.3 (4-6) (p<0.05). Significantly smaller variations were observed in the D+H group. The decrease in RF was 47.6% in the HR group vs 15.7% in the D+H group. The decrease in RAS was 40.9% in the HR group vs 12.8% in the D+H group. The decrease in ASLS was 64.8% in the HR group vs 12.9% in the comparative group. In conclusion venous microangiopathy and edema were improved by the treatment with HR both in the randomized study and in the pooled analysis. The comparison with D+H indicates that HR is comparatively more effective both on microcirculatory parameters and on signs/symptoms of CVI.

Angiology, Vol. 56, No. 1, 1-8 (2005)
DOI: 10.1177/000331970505600101


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
INT J LOW EXTREM WOUNDSHome page
U. Wollina, M. B. Abdel-Naser, and R. Mani
A Review of the Microcirculation in Skin in Patients With Chronic Venous Insufficiency: The Problem and the Evidence Available for Therapeutic Options
International Journal of Lower Extremity Wounds, September 1, 2006; 5(3): 169 - 180.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, A. Di Renzo, I. Ruffini, G. Gizzi, E. Ippolito, et al.
Venoruton(R) vs Daflon(R): Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency
Angiology, March 1, 2006; 57(2): 131 - 138.
[Abstract] [PDF]



Advertisement